Similarly, escalating cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibition with more frequent dosing or by increasing to a dose of 3 mg/kg as is done in other cancer types, usually with a limited number of ipilimumab doses, may increase efficacy endpoints with the possibility of greater toxicity.32 33 A direct comparison would be needed to better quantify alternative dosing schema. Here, CTLA4 is linked to cancer.